Temperature-sensitive liposome-mediated delivery of thrombolytic agents

International Journal of Hyperthermia

Volumn 31, Issue 1, 2015, Pages 67-73

  Saxena, Vishal ^a,b   Johnson, Carmen Gacchina ^a   Negussie, Ayele H ^a   Sharma, Karun V ^a,c   Dreher, Matthew R ^a   Wood, Bradford J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Staphylokinase; temperature sensitive liposomes; thrombolysis; tissue plasminogen activator

Indexed keywords

4 (2 HYDROXYETHYL) 1 PIPERAZINEETHANESULFONIC ACID; ALTEPLASE; DEXTRAN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; LIPOSOME; LOW TEMPERATURE SENSITIVE LIPOSOME; STAPHYLOKINASE; TEMPERATURE SENSITIVE LIPOSOME; TRADITIONAL TEMPERATURE SENSITIVE LIPOSOME; UNCLASSIFIED DRUG; UROKINASE; AUR PROTEIN, STAPHYLOCOCCUS AUREUS; FIBRINOLYTIC AGENT; LIPID; MACROGOL DERIVATIVE; METALLOPROTEINASE; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; ENZYMATIC ASSAY; ENZYME ACTIVITY; ENZYME RELEASE; FIBRINOLYSIS; HEATING; HIGH INTENSITY FOCUSED ULTRASOUND; HYPERTHERMIC THERAPY; LIPOSOMAL DELIVERY; MOLECULAR WEIGHT; PLASMA; SPECTROPHOTOMETRY; BLOOD CLOTTING; CHEMISTRY; DRUG EFFECTS; HUMAN; MALE; TEMPERATURE;

BLOOD COAGULATION; FIBRINOLYTIC AGENTS; HUMANS; HYPERTHERMIA, INDUCED; LIPIDS; LIPOSOMES; MALE; METALLOENDOPEPTIDASES; POLYETHYLENE GLYCOLS; TEMPERATURE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84925278481     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656736.2014.991428     Document Type: Article

References (52)

1. Pierce T, Razzuk M, Razzuk L, Hoover S. A comprehensive review of the physiology of hemostasis and antithrombotic agents. BUMC Proc 1999;12:39-49.
2. Patel SC, Mody A. Cerebral hemorrhagic complications of thrombolytic therapy. Prog Cardiovasc Dis 1999;42:217-33.
3. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991;78:3114-24.
4. Eppler S, Senn T, Gilkerson E, Modi NB. Pharmacokinetics and pharmacodynamics of recombinant tissue-type plasminogen activator following intravenous administration in rabbits: A comparison of three dosing regimens. Biopharm Drug Dispos 1998;19:31-8.
5. Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery - Liposomes versus lipid nanoparticles. Int J Nanomedicine 2007;2:595-607.
6. Nguyen PD, Orear EA, Johnson AE, Patterson E, Whitsett TL, Bhakta R. Accelerated thrombolysis and reperfusion in a canine model of myocardial-infarction by liposomal encapsulation of streptokinase. Circ Res 1990;66:875-8.
7. Tiukinhoy-Laing SD, Huang SL, Klegerman M, Holland CK, McPherson DD. Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes. Thromb Res 2007;119:777-84.
8. Vanderschueren S, Barrios L, Kerdsinchai P, Vandenheuvel P, Hermans L, Vrolix M, et al. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995;92:2044-9.
9. Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: A meta-analysis. JAMA 2014;311:2414-21.
10. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: An updated systematic review and meta-analysis. Lancet 2012;379:2364-72.
11. Cohen A. Pharmacokinetics of the recombinant thrombolytic agents - What is the clinical significance of their different pharmacokinetic parameters? Biodrugs 1999;11:115-23.
12. Modi NB, Eppler S, Breed J, Cannon CP, Braunwald E, Love TW. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thromb Haemostasis 1998;79:134-9.
13. Elbayoumi TA, Torchilin VP. Liposomes for targeted delivery of antithrombotic drugs. Expert Opin Drug Deliv 2008;5:1185-98.
14. Zhang X, Luckham PF, Hughes AD, Thom S, Xu XY. Development of lysolipid-based thermosensitive liposomes for delivery of high molecular weight proteins. Int J Pharmaceutics 2011;421:291-2.
15. Laing ST, Moody MR, Kim H, Smulevitz B, Huang SL, Holland CK, et al. Thrombolytic efficacy of tissue plasminogen activator-loaded echogenic liposomes in a rabbit thrombus model. Thromb Res 2012;130:629-35.
16. Tiukinhoy-Laing SD, Buchanan K, Parikh D, Huang SL, MacDonald RC, McPherson DD, et al. Fibrin targeting of tissue plasminogen activator-loaded echogenic liposomes. J Drug Target 2007;15:109-14.
17. Torchilin VP. Targeting of drugs and drug carriers within the cardiovascular system. Adv Drug Deliv Rev 1995;17:75-101.
18. Heeremans JLM, Prevost R, Bekkers MEA, Los P, Emeis JJ, Kluft C, et al. Thrombolytic treatment with tissue-type plasminogen-activator (t-PA)-containing liposomes in rabbits - A comparison with free t-PA. Thromb Haemostasis 1995;73:488-94.
19. May JP, Li SD. Hyperthermia-induced drug targeting. Expert Opin Drug Deliv 2013;10:511-27.
20. Lindner LH, Eichhorn ME, Eibl H, Teichert N, Schmitt-Sody M, Issels RD, et al. Novel temperature-sensitive liposomes with prolonged circulation time. Clin Cancer Res 2004;10:2168-78.
21. Lindner LH, Hossann M, Vogeser M, Teichert N, Wachholz K, Eibl H, et al. Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: Active ingredient and mediator of drug release. J Control Release 2008;125:112-20.
22. Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001;53:285-305.
23. Li L, ten Hagen TLM, Schipper D, Wijnberg TM, van Rhoon GC, Eggermont AMM, et al. Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J Control Release. 2010;143:274-9.
24. Lijnen HR, Vanhoef B, Decock F, Okada K, Ueshima S, Matsuo O, et al. On the mechanism of fibrin-specific plasminogen activation by staphlokinase. J Biol Chem 1991;266:11826-32.
25. Alexandrov AV. Current and future recanalization strategies for acute ischemic stroke. J Intern Med 2010;267:209-19.
26. Yeo LLL, Sharma VK. The quest for arterial recanalization in acute ischemic stroke - The past, present and the future. J Clin Med Res 2013;5:251-265.
27. Tapson VF. Thrombolytic therapy for acute pulmonary embolism. Semin Thromb Hemost 2013;39:7.
28. Block HS, Biller J. Commonly asked questions: Thrombolytic therapy in the management of acute stroke. Expert Rev Neurother 2013;13:157-65.
29. Stefanadis C, Diamantopoulos L, Vlachopoulos C, Tsiamis E, Dernellis J, Toutouzas K, et al. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo - A new method of detection by application of a special thermography catheter. Circulation 1999;99:1965-71.
30. Toutouzas K, Synetos A, Stefanadi E, Vaina S, Markou V, Vavuranakis M, et al. Correlation between morphologic characteristics and local temperature differences in culprit lesions of patients with symptomatic coronary artery disease. J Am Coll Cardiol 2007;49:2264-71.
31. Armstrong JK, Wenby RB, Meiselman HJ, Fisher TC. The hydrodynamic radii of macromolecules and their effect on red blood cell aggregation. Biophys J 2004;87:4259-70.
32. Scherphof G, Roerdink F, Waite M, Parks J. Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. Biochim Biophys Acta 1978;542:296-307.
33. Shabbits JA, Chiu GNC, Mayer LD. Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems. J Control Release 2002;84:161-70.
34. Hossann M, Syunyaeva Z, Schmidt R, Zengerle A, Eibl H, Issels RD, et al. Proteins and cholesterol lipid vesicles are mediators of drug release from thermosensitive liposomes. J Control Release 2012;162:400-6.
35. Shaw GJ, Meunier JM, Huang SL, Lindsell CJ, McPherson DD, Holland CK. Ultrasound-enhanced thrombolysis with tPA-loaded echogenic liposomes. Thromb Res 2009;124:306-10.
36. Vanderschueren S, Dens J, Kerdsinchai P, Desmet W, Vrolix M, DeMan F, et al. Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am Heart J 1997;134:213-19.
37. Mandi N, Soorapaneni S, Rewanwar S, Kotwal P, Prasad B, Mandal G, et al. High yielding recombinant staphylokinase in bacterial expression system-cloning, expression, purification and activity studies. Protein Expr Purif 2009;64:69-75.
38. Prasad B, Salunkhe SS, Padmanabhan S. Novel self-cleavage activity of staphylokinase fusion proteins: An interesting finding and its possible applications. Protein Expression Purification 2010;69:191-7.
39. Kumar S, Maheshwari N, Sahni G, inventors. Mutants of streptokinase and their covalently modified forms. US Patent 20100034804 A1, 2010.
40. Collen D, Bernaerts R, Declerck P, DeCock F, Demarsin E, Jenne S, et al. Recombinant staphylokinase variants with altered immunoreactivity. 1. Construction and characterization. Circulation 1996;94:197-206.
41. Collen D, Moreau H, Stockx L, Vanderschueren S. Recombinant staphylokinase variants with altered immunoreactivity. 1. Thrombolytic properties and antibody induction. Circulation 1996;94:207-16.
42. Collen D, DeCock F, Demarsin E, Jenne S, Lasters I, Laroche Y, et al. Recombinant staphylokinase variants with altered immunoreactivity. 3. Species variability of antibody binding patterns. Circulation 1997;95:455-62.
43. Liu J, Wang Z, He J, Wang G, Zhang R, Zhao B. Effect of site-specific PEGylation on the fibrinolytic activity, immunogenicity, and pharmacokinetics of staphylokinase. Acta Biochim Biophys Sin 2014;46:782-91.
44. Edgell T, McEvoy F, Webbon P, Gaffney PJ. Monoclonal antibodies to human fibrin: Interaction with other animal fibrins. Thromb Haemostasis 1996;75:595-9.
45. Klegerman ME, Zou Y, McPherson DD. Fibrin targeting of echogenic liposomes with inactivated tissue plasminogen activator. J Liposome Res 2008;18:95-112.
46. Sen Gupta A, Huang G, Lestini BJ, Sagnella S, Kottke-Marchant K, Marchant RE. RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system. Thromb Haemostasis 2005;93:106-14.
47. Peters D, Kastantin M, Kotamraju VR, Karmali PP, Gujraty K, Tirrell M, et al. Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci USA 2009;106:9815-19.
48. Frenkel V, Kimmel E, Iger Y. Ultrasound-induced cavitation damage to external epithelia of fish skin. Ultrasound Med Biol 1999;25:1295-303.
49. Nightingale K, Soo MS, Nightingale R, Trahey G. Acoustic radiation force impulse imaging: In vivo demonstration of clinical feasibility. Ultrasound Med Biol 2002;28:227-35.
50. Stone MJ, Frenkel V, Dromi S, Thomas P, Lewis RP, Li KC, et al. Pulsed high intensity focused ultrasound enhanced tPA mediated thrombolysis in a novel in vivo clot model: A pilot study. Thromb Res 2007;121:193-202.
51. Frenkel V, Oberoi J, Stone MJ, Park M, Deng C, Wood BJ, et al. Pulsed high-intensity focused ultrasound enhances thrombolysis in an in vitro model. Radiology 2006;239:86-93.
52. Lin PH, Annambhotla S, Bechara CF, Athamneh H, Weakley SM, Kobayashi K, et al. Comparison of percutaneous ultrasound-accelerated thrombolysis versus catheter-directed thrombolysis in patients with acute massive pulmonary embolism. Vascular 2009;17:S137-47.